Abstracts

163 – The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda

Background HIV incidence remains above global targets despite efficacious prevention and treatment products. We hypothesized that a SEARCH Community Precision Health intervention – using technology to connect people to HIV testing, prevention and treatment from community to clinic and back – would reduce population-level HIV incidence. Methods We conducted a cluster randomized controlled trial in…

171 – A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure

Background Durable, treatment-free control is a key goal of HIV cure research. While spontaneous controllers have been shown to exhibit functional HIV-specific CD8+ T cell responses to mutationally constrained (“networked”) epitopes, an even rarer group with no detectable provirus or proviruses confined to transcriptionally repressed genomic regions (e.g. ‘San Francisco patient’) demonstrates a depth of…

172 – Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART

Background Recent studies revealed discrete footprints of immune selection in the HIV reservoir cell pool, implying that human immune responses may be able to effectively engage and target these cells. However, the immune mechanisms driving the selection of reservoir cells remain unknown. Methods We performed single-genome, near full-length proviral next-generation sequencing to assess the frequencies…

177 – DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study

Background Doravirine (DOR) and islatravir (ISL; a nucleoside reverse transcriptase translocation inhibitor) are being studied in combination for the treatment of HIV. In people with virologically suppressed HIV-1, the efficacy of switching to DOR/ISL (100/0.25mg) was non-inferior to continuing prior antiretroviral therapy in 2 phase 3 studies. We report the efficacy and safety of DOR/ISL…

181 – Phase III Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1

Background Single tablet regimens (STRs) revolutionized HIV treatment, improving adherence and clinical outcomes; however, many people with HIV (PWH) on complex regimens (CRs) cannot take available STRs due to viral resistance, intolerance, contraindications, or drug-drug interactions. A novel STR of bictegravir (BIC) and lenacapavir (LEN) may offer an alternative treatment option. ARTISTRY-1 (NCT05502341) is a…